BSc BSc - Clovis Oncology Exec Officer
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Insider
BSc BSc is Exec Officer of Clovis Oncology
| Age | 54 |
| Phone | 303 625 5000 |
| Web | https://www.clovisoncology.com |
Clovis Oncology Management Efficiency
The company has return on total asset (ROA) of (0.3018) % which means that it has lost $0.3018 on every $100 spent on assets. This is way below average. Clovis Oncology's management efficiency ratios could be used to measure how well Clovis Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Clovis Oncology currently holds 436.77 M in liabilities with Debt to Equity (D/E) ratio of 810.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clovis Oncology has a current ratio of 1.15, suggesting that it is in a questionable position to pay out its financial obligations when due. Note, when we think about Clovis Oncology's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Rudolf Bless | Bank of America | N/A | |
| Michael Gualtieri | Comstock Holding Companies | N/A | |
| Trevor Gasper | Thor Industries | 43 | |
| Jerome Rouquet | Visteon Corp | 57 | |
| Jochen Ladwig | Visteon Corp | 45 | |
| William Swislow | Cars Inc | N/A | |
| Sharon Fitzgerald | Comstock Holding Companies | N/A | |
| Joseph IV | Gentex | 55 | |
| Thomas Scrivener | Bank of America | 51 | |
| BSc CPA | Montauk Renewables | 44 | |
| Robbin MooreRandolph | Cars Inc | N/A | |
| Brian Moynihan | Bank of America | 64 | |
| Jennifer Vianello | Cars Inc | N/A | |
| Wei Wei | Visteon Corp | N/A | |
| Renee Jones | Thor Industries | N/A | |
| Robert Wheeler | Thor Industries | N/A | |
| Christopher Hyzy | Bank of America | N/A | |
| Donald Wright | American Axle Manufacturing | N/A | |
| Sharon Frank | Montauk Renewables | N/A | |
| Mitch Golub | Cars Inc | N/A | |
| W Woelfer | Thor Industries | 53 | |
Management Performance
| Return On Asset | -0.3 |
Clovis Oncology Leadership Team
Elected by the shareholders, the Clovis Oncology's board of directors comprises two types of representatives: Clovis Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clovis. The board's role is to monitor Clovis Oncology's management team and ensure that shareholders' interests are well served. Clovis Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clovis Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna Sussman, VP Relations | ||
| Patrick MA, CEO, CoFounder | ||
| BSc BSc, Exec Officer | ||
| Paul Gross, Executive Vice President Chief Compliance Officer, General Counsel | ||
| Ann Bozeman, Executive Vice President of Human Resources | ||
| Thomas BSc, Ex Officer | ||
| Daniel Muehl, Principal Financial Officer, Principal Accounting Officer |
Clovis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clovis Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |